Stock Details
4519.T is Chugai Pharmaceutical Co., Ltd.'s stock. Stock exchange Tokyo (Currency JPY). Average price in 50 days is 4,196.29¥. Average daily volumn in 3 months 2.71M. Market cap 6.90T



Stock symbol : 4519.T. Exchange : Tokyo. Currency : JPY
Lastest price : 4,197.00¥. Total volume : 3.10M. Market state CLOSED
Click reload if you want to check the lastest price on market!!!

Chugai Pharmaceutical Co., Ltd. (4519.T)
Last Price
4,197.00¥
Change
70.00
Volume
3.10M

Previous Close4,127.00
Open4,149.00
Day Range4,135.00-4,199.00
Bid4,190.00 x N/A
Ask4,197.00 x N/A
Volume3.1M
Average Volume2.71M
Market Cap6.9T
Beta0.62
52 Week Range3,898.00-6,435.00
Trailing P/E32.78
Foward P/E4,035.58
Dividend (Yield %)1.44%
Ex-Dividend Date2021-12-29



Financial Details


According to Chugai Pharmaceutical Co., Ltd.'s financial reports the company's revenue in 2020 were 786.95B an increase( +14.58%) over the years 2019 revenue that were of 686.18B. In 2020 the company's total earnings were 214.73B while total earnings in 2019 were 157.56B( +36.31%).


Loading ...



Organization

Chugai Pharmaceutical Co., Ltd., together with its subsidiaries, engages in the research, development, manufacturing, sale, importation, and exportation of pharmaceuticals in Japan and internationally. The company's products for oncology primarily include Avastin, Tecentriq, Perjeta, Alecensa, Herceptin, Kadcyla, Rituxan, Gazyva, and Xeloda; osteoporosis, including Actemra, Edirol, and Bonviva; renal diseases consist of Mircera and Oxarol; and neurology/other diseases comprise Hemlibra, CellCept... , and Enspryng. It has various development product candidates in the areas of oncology, bone and joint diseases, autoimmune diseases, renal diseases, neurology, and other diseases. Chugai Pharmaceutical Co., Ltd. has strategic alliances with Roche Group; and collaboration and joint research with academia. The company was founded in 1925 and is headquartered in Tokyo, Japan. Chugai Pharmaceutical Co., Ltd. is a subsidiary of Roche Holding Ltd.

Chugai Pharmaceutical Co., Ltd._logo

Market Cap:
6.90T
Revenue:
786.95B
Total Assets:
1.24T
Total Cash:
212.33B


News about "Chugai Pharmaceutical Co., Ltd."

Esoteric Testing Market Industry Development, Global Growth Demand, Challenges, Forecast and Strategies To 2030 | Chugai Pharmaceutical Co., Ltd._image

Esoteric Testing Market Industry Development, Global Growth Demand, Challenges, Forecast and Strategies To 2030 | Chugai Pharmaceutical Co., Ltd.

Global Esoteric Testing Market Overview Emerging technologies such as biomarker analysis digital PCR NGS pyrosequencing or Sanger sequencing digital microfluidic platforms and advanced molecular ...

Source from : openpr.com - 3 days ago


Chugai Pharmaceutical Co. Ltd. ADR

1 Day CHGCY 1.73% DJIA 0.76% S&P 500 0.23% Health Care/Life Sciences -0.66% Tatsuro Kosaka Chairman & Chief Executive Officer Chugai Pharmaceutical Co., Ltd., Asahi Group Holdings Ltd. Osamu Okuda ...

Source from : Wall Street Journal - 5 days ago


Genentech's Covid-fighting drug in short supply just two months after FDA greenlight

Roche and subsidiary Chugai Pharmaceutical Co. Ltd. of Japan said they have ramped up manufacturing networks to maximize Actemra production and decided not to assert any patents in low- and middle ...

Source from : The Business Journals - 1 month ago


Chugai's ACTEMRA®/RoACTEMRA® Receives Breakthrough Therapy Designation from US FDA for Giant Cell Arteritis

-- The Fifth Breakthrough Therapy Designation Granted for a Chugai Originated Drug -- Chugai Pharmaceutical Co., Ltd. (TOKYO:4519) announced that the US Food and Drug Administration (FDA) has ...

Source from : ADVFN - 1 month ago


Protara Therapeutics Announces Second Quarter 2021 Financial Results and Business Overview

a broad immunopotentiator marketed as Picibanil in Japan and Taiwan by Chugai Pharmaceutical Co., Ltd. Protara has successfully demonstrated initial manufacturing comparability between TARA-002 ...

Source from : wallstreet online - 1 month ago


Human Herpesvirus 6-Associated Hemophagocytic Syndrome in a Healthy Adult

On day 14 after admission, at the onset of pancytopenia, subcutaneous administration of recombinant human G-CSF (Lenograstim; Chugai Pharmaceutical Co. LTD., Tokyo, Japan) was started at 2 µg/kg.

Source from : Medscape - 29 days ago


Histology of Symptomatic Gastroesophageal Reflux Disease

This was a multi-center, cooperative open study in Japan belonging to the Acid-Related Symptom (ARS) Research Group. The study was started after approval from the Ethics Committee of each medical ...

Source from : Medscape - 4 days ago


Chugai Pharmaceutical Co., Ltd.

Chugai Pharmaceutical Co., Ltd. engages in the research, development, manufacturing, sale, importation, and exportation of pharmaceuticals. Its operations are carried out through the Domestic and ...

Source from : NIKKEI - 9 days ago


Chugai Pharmaceutical Co Ltd 4519

Narrow moat Chugai’s reported second-quarter earnings that were in line with our expectations. Top-line revenue was JPY 221 billion, or 17% higher than the same period last year, mostly due to ...

Source from : Morningstar%2c Inc. - 5 days ago


Chugai Pharmaceutical Co Ltd CUP

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions.

Source from : Morningstar%2c Inc. - 5 days ago


Chugai Pharmaceutical Co. Ltd.

1 Day 4519 -0.02% DJIA 0.62% S&P 500 0.74% Health Care/Life Sciences -0.35% Tatsuro Kosaka Chairman & Chief Executive Officer Chugai Pharmaceutical Co., Ltd., Asahi Group Holdings Ltd. Osamu Okuda ...

Source from : Wall Street Journal - 22 days ago


Chugai Pharmaceutical Co., Ltd. (CHGCY)

*Close price adjusted for splits.**Adjusted close price adjusted for both dividends and splits. Loading more data ...

Source from : Yahoo Finance - 5 days ago


Chugai Pharmaceutical Co., Ltd. (4519.T)

S&P 500 falls 0.6% to pull back from record high and end 5-session winning streak ...

Source from : Yahoo Finance - 10 days ago


Chugai Pharmaceutical Co Ltd

If you are a California consumer, you have the right, at any time, to direct a business that sells your personal information to third parties to not sell your personal information. This right is ...

Source from : Reuters - 10 days ago


Chugai Pharmaceutical Co. Ltd.

Stocks: Real-time U.S. stock quotes reflect trades reported through Nasdaq only; comprehensive quotes and volume reflect trading in all markets and are delayed at least 15 minutes. International ...

Source from : Barron's - 29 days ago


Chugai Pharmaceutical Co. Ltd. ADR

Stocks: Real-time U.S. stock quotes reflect trades reported through Nasdaq only; comprehensive quotes and volume reflect trading in all markets and are delayed at least 15 minutes. International ...

Source from : Barron's - 10 days ago


Chugai Pharmaceutical Co Ltd (CHGCF)

Investors may trade in the Pre-Market (4:00-9:30 a.m. ET) and the After Hours Market (4:00-8:00 p.m. ET). Participation from Market Makers and ECNs is strictly voluntary and as a result, these ...

Source from : Nasdaq - 2 month ago


Chugai Pharmaceutical Co Ltd (CHGCF)

©2021, EDGAR®Online, a division of Donnelley Financial Solutions. EDGAR® is a federally registered trademark of the U.S. Securities and Exchange Commission. EDGAR ...

Source from : Nasdaq - 1 year ago


Chugai Pharmaceutical Co., Ltd. (CHGCY)

*Close price adjusted for splits.**Adjusted close price adjusted for both dividends and splits. Loading more data ...

Source from : Yahoo Finance - 10 days ago


Verastem Oncology Reports Second Quarter 2021 Financial Results and Highlights Recent Company Progress

that we or Chugai Pharmaceutical Co., Ltd. will fail to fully perform under the VS-6766 license agreement; that we may not have sufficient cash to fund our contemplated operations; that we may be ...

Source from : Yahoo Finance - 1 month ago


F. Hoffmann-La Roche Ltd: Roche opens access to pathology imaging tools to improve patient care

Roche launches the Digital Pathology Open Environment, encouraging collaboration among software developers to improve patient outcomes and expand personalised healthcare through innovative image analy ...

Source from : Finanznachrichten - 4 month ago


Japan turns to antibody cocktails as 'new weapon' in fight against pandemic

The antibody treatment — originally developed by American biotech firm Regeneron Pharmaceuticals Inc. and licensed in Japan by Tokyo-based drugmaker Chugai Pharmaceutical Co. — has drawn ...

Source from : The Japan Times - 25 days ago


Verastem Oncology Reports Second Quarter 2021 Financial Results and Highlights Recent Company Progress

that we or Chugai Pharmaceutical Co., Ltd. will fail to fully perform under the VS-6766 license agreement; that we may not have sufficient cash to fund our contemplated operations; that we may be ...

Source from : Yahoo Finance - 1 month ago


Uveitis Drug Pipeline Landscape Research Report 2021 - ResearchAndMarkets.com

PharmiWeb.com is Europe's leading industry-sponsored portal for the Pharmaceutical sector, providing the latest jobs, news, features and events listings. The information provided on PharmiWeb.com is ...

Source from : PharmiWeb - 5 days ago


Uveitis Drug Pipeline Landscape Research Report 2021 - ResearchAndMarkets.com

The "Uveitis (Ophthalmology) - Drugs In Development, 2021" report has been added to ResearchAndMarkets.com's offering. Uveitis - Drugs In Development, 2021, provides an overview of the Uveitis ...

Source from : The Register-Herald - 5 days ago


Pegfilgrastim Market Share 2021 Strategy Analysis, Top Manufacturers, Industry Size, Types, Application, Growth Factor and Forecast to 2026

Is there a problem with this press release? Contact the source provider Comtex at [email protected] You can also contact MarketWatch Customer Service via our Customer Center. The MarketWatch ...

Source from : MarketWatch - 1 month ago


Roche opens access to pathology imaging tools to improve patient care_image

Roche opens access to pathology imaging tools to improve patient care

Roche launches the Digital Pathology Open Environment, encouraging collaboration among software developers to improve patient outcomes and expand personalised healthcare through innovative image ...

Source from : Yahoo Canada Sports - 3 days ago


Porokeratosis Treatment Market is Surging on the Back Rising Focus on Skincare: Fact.MR

The global porokeratosis treatment market is demonstrating a steady growth due to surge demand for laser treatment, kidney transplant, and improved reimbursement policies. The distribution of actinic ...

Source from : PharmiWeb - 9 days ago


Roche opens access to pathology imaging tools to improve patient care

Roche is the majority shareholder in Chugai Pharmaceutical, Japan. For more information, please visit www.roche.com. All trademarks used or mentioned in this release are protected by law.

Source from : Yahoo News - 3 days ago


Roche opens access to pathology imaging tools to improve patient care

Roche is the majority shareholder in Chugai Pharmaceutical, Japan. For more information, please visit www.roche.com. All trademarks used or mentioned in this release are protected by law.

Source from : wallstreet online - 3 days ago


Uveitis Drug Pipeline Landscape Research Report 2021 - ResearchAndMarkets.com

DUBLIN, September 13, 2021--(BUSINESS WIRE)--The "Uveitis (Ophthalmology) - Drugs In Development, 2021" report has been added to ResearchAndMarkets.com's offering. Uveitis - Drugs In Development, 2021 ...

Source from : Yahoo Finance - 5 days ago


Uveitis Drug Pipeline Landscape Research Report 2021 - ResearchAndMarkets.com

DUBLIN, September 13, 2021--(BUSINESS WIRE)--The "Uveitis (Ophthalmology) - Drugs In Development, 2021" report has been added to ResearchAndMarkets.com's offering. Uveitis - Drugs In Development, 2021 ...

Source from : Yahoo Finance - 5 days ago


Roche warns of shortage of Covid-19 drug tocilizumab

In July, Médecins Sans Frontières/Doctors Without Borders (MSF) had called on Swiss pharmaceutical company Roche, the world’s sole producer of the drug, to lower the price of the drug to make ...

Source from : Business Line - 1 month ago


Uveitis Drug Pipeline Landscape Research Report 2021 - ResearchAndMarkets.com

DUBLIN, September 13, 2021--(BUSINESS WIRE)--The "Uveitis (Ophthalmology) - Drugs In Development, 2021" report has been added to ResearchAndMarkets.com's offering. Uveitis - Drugs In Development, 2021 ...

Source from : Yahoo Finance - 5 days ago


American Depository Receipt Stocks A-Z

ADR (EBR.B) United States XNYS Renewable Energy Generation China Longyuan Power Group Corp. Ltd. ADR (CLPXY) United States OOTC Renewable Energy Generation China Mengniu Dairy Co. Ltd. ADR (CIADY ...

Source from : MarketWatch - 16 days ago


Japan's Nikkei ends at near 6-month high on bargain hunting for cheap stocks

JFE Holdings, which fell 1.94%, was the worst performer on the index, followed by Chugai Pharmaceutical , losing 1.86% and Nippon Express, which fell 1.48%.

Source from : Yahoo Finance - 10 days ago


Roche to present data from industry leading portfolio at ESMO 2021 showing significant progress in early stage and uncommon cancers

First data to be presented from the phase II coopERA Breast Cancer study evaluating neoadjuvant giredestrant treatment for oestrogen receptor (ER)-positive, HER2-negative breast cancer New data from ...

Source from : Yahoo Finance - 11 days ago


External Professional Relationships and Financial Interests

Doctors and faculty members often work with pharmaceutical, device, biotechnology, and life sciences companies, and other organizations outside of MSK, to find safe and effective cancer treatments, to ...

Source from : mskcc.org - 11 month ago


Roche to present data from industry leading portfolio at ESMO 2021 showing significant progress in early stage and uncommon cancers

First data to be presented from the phase II coopERA Breast Cancer study evaluating neoadjuvant giredestrant treatment for oestrogen receptor (ER)-positive, HER2-negative breast cancer New data from ...

Source from : Yahoo Finance - 11 days ago


Marshall, Gerstein & Borun LLP

Founded in 1955 as Merriam & Lorch in the Chicago Board of Trade building, Marshall, Gerstein & Borun originally focused on the electrical, chemical, and pharmaceutical industries. Over the next 57 ...

Source from : Vault - 2 years ago


New drug for difficult-to-drug cancer mutation could be key treatment for a range of cancers

The researchers found that CH5126766/VS-6766, now under development by pharmaceutical company Verastem Oncology, was safe for patients when treated using the intermittent schedule, with manageable ...

Source from : icr.ac.uk - 10 month ago


Pharma appointments, March 2012

Previously, he was global head of partnering at Roche as well as a member of the Roche corporate executive committee and the board of Roche's Japan-based subsidiary Chugai ... has spent 16 years ...

Source from : PMLiVE - 9 years ago